Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1′-pyrrolidinone or P2-tris-tetrahydrofuran

Journal of Medicinal Chemistry

Volumn 56, Issue 10, 2013, Pages 4017-4027

  Agniswamy, Johnson ^a   Shen, Chen Hsiang ^a   Wang, Yuan Fang ^a   Ghosh, Arun K ^b   Rao, Kalapala Venkateswara ^b   Xu, Chun Xiao ^b   Sayer, Jane M ^c   Louis, John M ^c   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; ARGININE; ATAZANAVIR; DARUNAVIR; GRL 02031; GRL 0519; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LEUCINE; PHENYLALANINE; PYRROLIDINE DERIVATIVE; PYRROLIDINONE; SAQUINAVIR; TETRAHYDROFURAN DERIVATIVE; TRIS TETRAHYDROFURAN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOTHERMAL TITRATION CALORIMETRY; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; VIRUS STRAIN; WILD TYPE;

BINDING SITES; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMATES; CRYSTALLIZATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; ESCHERICHIA COLI; FURANS; GENES, SYNTHETIC; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION; PYRROLIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84878067703     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400231v     Document Type: Article

References (47)

1. Sepkowitz, K. A. AIDS-the first 20 years N. Engl. J. Med. 2001, 344, 1764-1772
2. Condra, J. H.; Schleif, W. A.; Blahy, O. M.; Gabryelski, L. J.; Graham, D. J.; Quintero, J. C.; Rhodes, A.; Robbins, H. L.; Roth, E.; Shivaprakash, M. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature 1995, 374, 569-571
3. Mehellou, Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J. Med. Chem. 2010, 53, 521-538
4. Menendez-Arias, L. Molecular basis of human immunodeficiency virus drug resistance: an update Antiviral Res. 2010, 85, 210-231
5. Grubb, J. R.; Singhatiraj, E.; Mondy, K.; Powderly, W. G.; Overton, E. T. Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic AIDS 2006, 20, 2115-2116
6. Liao, L.; Xing, H.; Dong, Y.; Qin, G.; Ma, Y.; Lu, H.; Chen, L.; Zhang, L.; Osborne, C.; Seguy, N.; Wei, D.; Sun, F.; Yang, J.; Ruan, Y.; Shao, Y. Surveys of Transmitted HIV Drug Resistance in 7 Geographic Regions in China, 2008-2009 Clin. Infect. Dis. 2012, 54 (Suppl 4) S320-S323
7. Hunt, G. M.; Ledwaba, J.; Basson, A. E.; Moyes, J.; Cohen, C.; Singh, B.; Bertagnolio, S.; Jordan, M. R.; Puren, A.; Morris, L. Surveillance of Transmitted HIV-1 Drug Resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009 Clin. Infect. Dis. 2012, 54 (Suppl 4) S334-S338
8. Duc, N. B.; Hien, B. T.; Wagar, N.; Tram, T. H.; Giang le, T.; Yang, C.; Wolfe, M. I.; Hien, N. T.; Tuan, N. A. Surveillance of Transmitted HIV Drug Resistance Using Matched Plasma and Dried Blood Spot Specimens From Voluntary Counseling and Testing Sites in Ho Chi Minh City, Vietnam, 2007-2008 Clin. Infect. Dis. 2012, 54 (Suppl 4) S343-S347
9. Hamers, R. L.; Wallis, C. L.; Kityo, C.; Siwale, M.; Mandaliya, K.; Conradie, F.; Botes, M. E.; Wellington, M.; Osibogun, A.; Sigaloff, K. C.; Nankya, I.; Schuurman, R.; Wit, F. W.; Stevens, W. S.; van Vugt, M.; de Wit, T. F. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study Lancet Infect. Dis. 2011, 11, 750-759
10. Sigaloff, K. C.; Mandaliya, K.; Hamers, R. L.; Otieno, F.; Jao, I. M.; Lyagoba, F.; Magambo, B.; Kapaata, A.; Ndembi, N.; Rinke de Wit, T. F. High Prevalence of Transmitted Antiretroviral Drug Resistance Among Newly HIV Type 1 Diagnosed Adults in Mombasa, Kenya AIDS Res. Hum. Retroviruses 2012, 28, 1033-1037
11. Jordan, M. R.; Bennett, D. E.; Wainberg, M. A.; Havlir, D.; Hammer, S.; Yang, C.; Morris, L.; Peeters, M.; Wensing, A. M.; Parkin, N.; Nachega, J. B.; Phillips, A.; De Luca, A.; Geng, E.; Calmy, A.; Raizes, E.; Sandstrom, P.; Archibald, C. P.; Perriens, J.; McClure, C. M.; Hong, S. Y.; McMahon, J. H.; Dedes, N.; Sutherland, D.; Bertagnolio, S. Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011 Clin. Infect. Dis. 2012, 54 (Suppl 4) S245-S249
12. Hirsch, M. S.; Gunthard, H. F.; Schapiro, J. M.; Brun-Vezinet, F.; Clotet, B.; Hammer, S. M.; Johnson, V. A.; Kuritzkes, D. R.; Mellors, J. W.; Pillay, D.; Yeni, P. G.; Jacobsen, D. M.; Richman, D. D. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel Clin. Infect. Dis. 2008, 47, 266-285
13. Heneine, W.; Kashuba, A. HIV Prevention by Oral Preexposure Prophylaxis Cold Spring Harb. Perspect. Med. 2012, 2, a007419
14. Supervie, V.; Garcia-Lerma, J. G.; Heneine, W.; Blower, S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 12381-12386
15. Louis, J. M.; Aniana, A.; Weber, I. T.; Sayer, J. M. Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 9072-9077
16. Agniswamy, J.; Shen, C. H.; Aniana, A.; Sayer, J. M.; Louis, J. M.; Weber, I. T. HIV-1 Protease with 20 Mutations Exhibits Extreme Resistance to Clinical Inhibitors through Coordinated Structural Rearrangements Biochemistry 2012, 51, 2819-2828
17. Flexner, C. HIV drug development: the next 25 years Nature Rev. Drug Discovery 2007, 6, 959-966
18. Williams, G. C.; Sinko, P. J. Oral absorption of the HIV protease inhibitors: a current update Adv. Drug Delivery Rev. 1999, 39, 211-238
19. Ghosh, A. K.; Leshchenko-Yashchuk, S.; Anderson, D. D.; Baldridge, A.; Noetzel, M.; Miller, H. B.; Tie, Y.; Wang, Y. F.; Koh, Y.; Weber, I. T.; Mitsuya, H. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1′-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies J. Med. Chem. 2009, 52, 3902-3914
20. Ghosh, A. K.; Xu, C. X.; Rao, K. V.; Baldridge, A.; Agniswamy, J.; Wang, Y. F.; Weber, I. T.; Aoki, M.; Miguel, S. G.; Amano, M.; Mitsuya, H. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors ChemMedChem 2010, 5, 1850-1854
21. Ghosh, A. K.; Anderson, D. D.; Weber, I. T.; Mitsuya, H. Enhancing protein backbone binding-a fruitful concept for combating drug-resistant HIV Angew. Chem., Int. Ed. Engl. 2012, 51, 1778-1802
22. Kovalevsky, A. Y.; Liu, F.; Leshchenko, S.; Ghosh, A. K.; Louis, J. M.; Harrison, R. W.; Weber, I. T. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114 J. Mol. Biol. 2006, 363, 161-173
23. Kovalevsky, A. Y.; Ghosh, A. K.; Weber, I. T. Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir J. Med. Chem. 2008, 51, 6599-6603
24. Mahalingam, A. K.; Axelsson, L.; Ekegren, J. K.; Wannberg, J.; Kihlstrom, J.; Unge, T.; Wallberg, H.; Samuelsson, B.; Larhed, M.; Hallberg, A. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells J. Med. Chem. 2010, 53, 607-615
25. Shen, C. H.; Wang, Y. F.; Kovalevsky, A. Y.; Harrison, R. W.; Weber, I. T. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters FEBS J. 2010, 277, 3699-3714
26. Tie, Y.; Wang, Y. F.; Boross, P. I.; Chiu, T. Y.; Ghosh, A. K.; Tozser, J.; Louis, J. M.; Harrison, R. W.; Weber, I. T. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors Protein Sci. 2012, 21, 339-350
27. Koh, Y.; Das, D.; Leschenko, S.; Nakata, H.; Ogata-Aoki, H.; Amano, M.; Nakayama, M.; Ghosh, A. K.; Mitsuya, H. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro Antimicrob. Agents Chemother. 2009, 53, 997-1006
28. Chang, Y. C.; Yu, X.; Zhang, Y.; Tie, Y.; Wang, Y. F.; Yashchuk, S.; Ghosh, A. K.; Harrison, R. W.; Weber, I. T. Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1′-pyrrolidinone ring J. Med. Chem. 2012, 55, 3387-3397
29. Kozisek, M.; Bray, J.; Rezacova, P.; Saskova, K.; Brynda, J.; Pokorna, J.; Mammano, F.; Rulisek, L.; Konvalinka, J. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants J. Mol. Biol. 2007, 374, 1005-1016
30. Bihani, S. C.; Das, A.; Prashar, V.; Ferrer, J. L.; Hosur, M. V. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S Biochem. Biophys. Res. Commun. 2009, 389, 295-300
31. Zhang, H.; Wang, Y. F.; Shen, C. H.; Agniswamy, J.; Rao, K. V.; Ghosh, A. K.; Harrison, R. W.; Weber, I. T. Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease J. Med. Chem. 2013, 56, 1074-1083
32. Mahalingam, B.; Louis, J. M.; Hung, J.; Harrison, R. W.; Weber, I. T. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes Proteins 2001, 43, 455-464
33. King, N. M.; Prabu-Jeyabalan, M.; Nalivaika, E. A.; Wigerinck, P.; de Bethune, M. P.; Schiffer, C. A. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor J. Virol. 2004, 78, 12012-12021
34. King, N. M.; Prabu-Jeyabalan, M.; Bandaranayake, R. M.; Nalam, M. N.; Nalivaika, E. A.; Ozen, A.; Haliloglu, T.; Yilmaz, N. K.; Schiffer, C. A. Extreme Entropy-Enthalpy Compensation in a Drug-Resistant Variant of HIV-1 Protease ACS Chem. Biol. 2012, 7, 1536-1546
35. Huang, L.; Li, Y.; Chen, C. Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions Retrovirology 2011, 8, 79
36. Davis, D. A.; Soule, E. E.; Davidoff, K. S.; Daniels, S. I.; Naiman, N. E.; Yarchoan, R. Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors Against the Initial Autocleavage in Gag-Pol Polyprotein Processing Antimicrob. Agents Chemother. 2012, 56, 3620-3628
37. Dierynck, I.; De Wit, M.; Gustin, E.; Keuleers, I.; Vandersmissen, J.; Hallenberger, S.; Hertogs, K. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier J. Virol. 2007, 81, 13845-13851
38. Sayer, J. M.; Agniswamy, J.; Weber, I. T.; Louis, J. M. Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance Protein Sci. 2010, 19, 2055-2072
39. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 1997, 276, 307-326
40. Storoni, L. C.; McCoy, A. J.; Read, R. J. Likelihood-enhanced fast rotation functions Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 432-438
41. McCoy, A. J.; Grosse-Kunstleve, R. W.; Storoni, L. C.; Read, R. J. Likelihood-enhanced fast translation functions Acta Crystallogr., Sect. D: Biol. Crystallogr. 2005, 61, 458-464
42. Kovalevsky, A. Y.; Tie, Y.; Liu, F.; Boross, P. I.; Wang, Y. F.; Leshchenko, S.; Ghosh, A. K.; Harrison, R. W.; Weber, I. T. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M J. Med. Chem. 2006, 49, 1379-1387
43. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132
44. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255
45. Sheldrick, G. M.; Schneider, T. R. SHELXL: high-resolution refinement Methods Enzymol. 1997, 277, 319-343
46. Weber, I. T.; Wang, Y,-F. HIV protease: role in viral replication, protein-ligand X-ray crystal structures and inhibitor design. In Aspartic Protease as Therapeutic Targets; Gosh, A. K., Ed.; Wiley-VCH Verlag GmbH & Co.: New York, 2010; Vol. 45, pp 109-137.
47. Panigrahi, S. K.; Desiraju, G. R. Strong and weak hydrogen bonds in the protein-ligand interface Proteins 2007, 67, 128-141